Peregrine's Cotara effective against brain cancer in study

06/17/2009 | Pharmaceutical Business Review Online

A dosing and dosimetry study showed that Cotara, a monoclonal antibody attached to a radioisotope, allowed patients with glioblastoma multiforme, a type of brain cancer, to meet or surpass the expected six-month median survival period. The findings validate Cotara's "ability to specifically concentrate in and deliver a high radiation dose to brain tumors," said an official from Peregrine Pharmaceuticals, which developed the treatment.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ